Intravenous Immunoglobulin 10% in Children with Primary Immunodeficiency Diseases
Assessed the safety and efficacy of Panzyga in preventing serious bacterial infections (SBIs) in predominantly antibody-deficient children with PI disease, finding it effective, well-tolerated, and safe for both children and adolescents during 12-15 months of treatment.1
Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga) in Patients with Primary Immunodeficiency Diseases
Analyzed the efficacy and safety of Panzyga in preventing serious bacterial infections (SBIs) in patients with PI, finding that its use with antibody-deficient PI patients was associated with a low rate of adverse events (AEs) and was effective in preventing SBIs.2
Pharmacokinetics of a Novel Human Intravenous Immunoglobulin 10% in Patients with Primary Immunodeficiency Diseases
Investigated the pharmacokinetics of Panzyga in patients aged 2-75 years with CVID or X-linked agammaglobulinaemia, finding its pharmacokinetic properties similar to those of other commercial preparations and that 3- or 4-weekly administration achieved sufficient concentrations of IgG/IgG subclasses/specific antibodies needed to prevent serious bacterial infections.3
Efficacy and Safety of a New Intravenous Immunoglobulin (Panzyga) in Chronic Immune Thrombocytopenia
Assessed the efficacy and safety of Panzyga, a novel human normal IVIg 10%, in adult patients with chronic ITP, finding it well tolerated even at a high infusion speed, inducing a rapid platelet count increase, thus decreasing rate and severity of bleeding events.4
ProCID Trial of Panzyga for CIDP
The Progress in Chronic Inflammatory Demyelinating polyneuropathy (ProCID) dose-ranging study investigated the efficacy, tolerability, and safety of a standard loading dose of Panzyga followed by 3 alternative maintenance dosing levels, finding that the 1.0 and 2.0 g/kg dosing levels were efficacious and well tolerated as maintenance treatment for CIDP in adults.5
A closer look at study design and protocol of the ProCID randomized, multicenter, phase III study of intravenous immunoglobulin 10% in adult patients with chronic inflammatory demyelinating polyradiculoneuropathy.6
Fast Facts: Panzyga for Treatment of PI & cITP
A handy reference overview of the safety, tolerability, and efficacy of Panzyga used in the treatment of PI and cITP, along with recommended dosing and administration rates for both disease states.
Fast Facts: Panzyga for Treatment of CIDP
A handy reference overview of the safety, tolerability, and efficacy of a standard loading dose and two FDA-approved maintenance dosing options for Panzyga used in the treatment of CIDP in adults.
For help calculating the appropriate infusion rate for loading and maintenance dosing for your patients with PI, cITP, and CIDP.